Literature DB >> 21755295

Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells.

Malin Dahl1, Pierre Bouchelouche, Gabriela Kramer-Marek, Jacek Capala, Jørgen Nordling, Kirsten Bouchelouche.   

Abstract

Increasing evidence suggests that Human epidermal growth factor receptor 2 (HER2/neu) is involved in progression of prostate cancer. Recently, sarcosine was reported to be highly increased during prostate cancer progression, and exogenous sarcosine induces an invasive phenotype in benign prostate epithelial cells. The aim of this work was to investigate the effect of sarcosine on HER2/neu expression in prostate cancer cell lines LNCaP (androgen dependent), PC-3 and DU145 (both androgen independent). Relative amounts of HER2/neu and androgen receptor (AR) transcripts were determined using RT-qPCR. Total expression of HER2/neu was confirmed by Western blot (WB). HER2/neu protein on the surface of living LNCaP cells was visualized by confocal microscopy using a HER2/neu-specific fluorescent probe. Exposure of LNCaP cells to 50 μM sarcosine for 24 h resulted in a 58% increase of the HER2/neu mRNA level (P < 0.001) indicating that sarcosine effects HER2/neu expression on the level of transcription. Control experiments with alanine, an isomer of sarcosine, showed no significant effect on HER2/neu transcription. The upregulation of HER2/neu mRNA preceded the corresponding increment of the protein level after the 48-h exposure to sarcosine as shown by WB and confocal microscopy. Interestingly, sarcosine had no effect on the activated (phosphorylated) form of HER2/neu. No significant change in AR expression was observed after exposure to sarcosine. This is the first report indicating that sarcosine is involved in the regulation of the oncoprotein HER2/neu. Thus, sarcosine may induce prostate cancer progression by increased HER2/neu expression. However, detailed information on cellular mechanisms remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21755295      PMCID: PMC3402037          DOI: 10.1007/s11033-010-0442-2

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  19 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Her-2-neu expression and progression toward androgen independence in human prostate cancer.

Authors:  S Signoretti; R Montironi; J Manola; A Altimari; C Tam; G Bubley; S Balk; G Thomas; I Kaplan; L Hlatky; P Hahnfeldt; P Kantoff; M Loda
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

3.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

Authors:  D J Slamon; W Godolphin; L A Jones; J A Holt; S G Wong; D E Keith; W J Levin; S G Stuart; J Udove; A Ullrich
Journal:  Science       Date:  1989-05-12       Impact factor: 47.728

Review 4.  The basic biology of HER2.

Authors:  I Rubin; Y Yarden
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

5.  Androgen-dependent regulation of Her-2/neu in prostate cancer cells.

Authors:  Raanan Berger; Douglas I Lin; Maria Nieto; Ewa Sicinska; Levi A Garraway; Heiner Adams; Sabina Signoretti; William C Hahn; Massimo Loda
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

6.  Preoperative plasma HER2 and epidermal growth factor receptor for staging and prognostication in patients with clinically localized prostate cancer.

Authors:  Shahrokh F Shariat; Karim Bensalah; Jose A Karam; Claus G Roehrborn; Andrea Gallina; Yair Lotan; Kevin M Slawin; Pierre I Karakiewicz
Journal:  Clin Cancer Res       Date:  2007-09-15       Impact factor: 12.531

7.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

Review 8.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

9.  Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression.

Authors:  Arun Sreekumar; Laila M Poisson; Thekkelnaycke M Rajendiran; Amjad P Khan; Qi Cao; Jindan Yu; Bharathi Laxman; Rohit Mehra; Robert J Lonigro; Yong Li; Mukesh K Nyati; Aarif Ahsan; Shanker Kalyana-Sundaram; Bo Han; Xuhong Cao; Jaeman Byun; Gilbert S Omenn; Debashis Ghosh; Subramaniam Pennathur; Danny C Alexander; Alvin Berger; Jeffrey R Shuster; John T Wei; Sooryanarayana Varambally; Christopher Beecher; Arul M Chinnaiyan
Journal:  Nature       Date:  2009-02-12       Impact factor: 49.962

10.  LNCaP model of human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; E Kawinski; J P Karr; H Rosenthal; T M Chu; E A Mirand; G P Murphy
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

View more
  11 in total

1.  Regulation of the metabolite profile by an APC gene mutation in colorectal cancer.

Authors:  Tomoo Yoshie; Shin Nishiumi; Yoshihiro Izumi; Aya Sakai; Jun Inoue; Takeshi Azuma; Masaru Yoshida
Journal:  Cancer Sci       Date:  2012-04-12       Impact factor: 6.716

Review 2.  Combination strategies to enhance antitumor ADCC.

Authors:  Holbrook E Kohrt; Roch Houot; Aurélien Marabelle; Hearn Jay Cho; Keren Osman; Matthew Goldstein; Ronald Levy; Joshua Brody
Journal:  Immunotherapy       Date:  2012-05       Impact factor: 4.196

Review 3.  Metabolomic profiling of hormone-dependent cancers: a bird's eye view.

Authors:  Stacy M Lloyd; James Arnold; Arun Sreekumar
Journal:  Trends Endocrinol Metab       Date:  2015-08-01       Impact factor: 12.015

4.  A Washing-Free and Easy-to-Operate Fluorescent Biosensor for Highly Efficient Detection of Breast Cancer-Derived Exosomes.

Authors:  Wenqin Chen; Yan Zhang; Kaili Di; Chang Liu; Yanyan Xia; Shijia Ding; Han Shen; Zhiyang Li
Journal:  Front Bioeng Biotechnol       Date:  2022-06-28

5.  Expression of sarcosine metabolism-related proteins in estrogen receptor negative breast cancer according to the androgen receptor and HER-2 status.

Authors:  Min Ju Kim; Woo Hee Jung; Ja Seung Koo
Journal:  Int J Clin Exp Pathol       Date:  2015-07-01

Review 6.  Sarcosine as a potential prostate cancer biomarker--a review.

Authors:  Natalia Cernei; Zbynek Heger; Jaromir Gumulec; Ondrej Zitka; Michal Masarik; Petr Babula; Tomas Eckschlager; Marie Stiborova; Rene Kizek; Vojtech Adam
Journal:  Int J Mol Sci       Date:  2013-07-04       Impact factor: 5.923

7.  High Performance Liquid Chromatography-mass Spectrometry Analysis of High Antioxidant Australian Fruits with Antiproliferative Activity Against Cancer Cells.

Authors:  Joseph Sirdaarta; Anton Maen; Paran Rayan; Ben Matthews; Ian Edwin Cock
Journal:  Pharmacogn Mag       Date:  2016-05-11       Impact factor: 1.085

8.  AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role.

Authors:  Kuang-Ti Chen; Mang-Hung Tsai; Ching-Hsiang Wu; Ming-Jia Jou; I-Hua Wei; Chih-Chia Huang
Journal:  Front Behav Neurosci       Date:  2015-06-18       Impact factor: 3.558

9.  Implications of differences in expression of sarcosine metabolism-related proteins according to the molecular subtype of breast cancer.

Authors:  Ja Kyung Yoon; Do Hee Kim; Ja Seung Koo
Journal:  J Transl Med       Date:  2014-05-28       Impact factor: 5.531

10.  Sarcosine Up-Regulates Expression of Genes Involved in Cell Cycle Progression of Metastatic Models of Prostate Cancer.

Authors:  Zbynek Heger; Miguel Angel Merlos Rodrigo; Petr Michalek; Hana Polanska; Michal Masarik; Vitezslav Vit; Mariana Plevova; Dalibor Pacik; Tomas Eckschlager; Marie Stiborova; Vojtech Adam
Journal:  PLoS One       Date:  2016-11-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.